Navigation Links
Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
Date:8/5/2008

The most common moderate/severe related adverse events in the once-daily and twice-daily groups respectively were: diarrhea (17 percent versus 15 percent), nausea (seven percent versus five percent), vomiting (three percent versus four percent), and increased triglycerides (two percent in both groups). There was no statistical difference between the groups.

-- At week 48, the overall impact of Kaletra, dosed once-daily or twice-daily, on grade 3-4 lab abnormalities, including cholesterol and triglycerides, the liver enzymes, SGOT/AST, and creatinine clearance was similar.

-- At week 48, there was a statistically significant difference in the increase of total cholesterol between the once-daily and twice-daily group.

About Abbott's Commitment to Fighting HIV/AIDS

HIV/AIDS is a global problem that demands shared commitment and shared responsibility. Abbott is committed to working with governments, multilateral organizations, nongovernmental organizations and patient groups to expand access to HIV treatments around the world. Abbott has also made significant investments in expanding manufacturing capacity to meet the growing demand for HIV treatment in developing countries.

Abbott's lopinavir/ritonavir formulations are among the lowest-priced protease inhibitors in the developing world. Abbott has been providing its HIV medicines at a price of US$500 per adult patient per year in all African and least developed countries since 2002, making these medicines more affordable than any generic copies.

Abbott and the company's philanthropic foundation, Abbott Fund, have invested more than US$100 million in the fight against HIV/AIDS in Africa and the developing world. Abbott Fund-supported programs have served more than 700,000 children and families. In addition, more than 250,000 patients have been tested through Abbott Fund-supported voluntary counseling and testing programs, with thousands being referred to treatment programs. Abb
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
2. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
3. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
4. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
5. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
6. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
7. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
8. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
9. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
10. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
11. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015 ... (Homofermentative & Heterofermentative), Species (Lactobacillus, Pediococcus & Enterococcus), Enzymes ... and Forecast to 2020", Silage Inoculants & Enzymes Market ... a CAGR of 4.0% from 2015 to 2020. ... igures spread through 194 P ...
(Date:7/2/2015)... 2015 BGI gab heute bekannt, ... vom American College of Pathologists (CAP) akkreditiert ... erste klinische Next-Generation-Sequencing Labor, das in ... und somit die höchsten Standards an klinischer ... FDA - 21 CFR Part 11 konformen ...
(Date:7/2/2015)... , July 2, 2015  AbbVie (NYSE: ... on Friday, July 24, 2015, before the market opens. ... the earnings conference call at 8 a.m. Central time ... Investor Relations website at www.abbvieinvestor.com . An archived ... a.m. Central time. About AbbVie ...
Breaking Medicine Technology:Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4BGI erhält Akkreditierung vom College of American Pathologists (CAP) 2
(Date:7/3/2015)... MO (PRWEB) , ... July 03, 2015 , ... Talcum ... website to replace their existing Talcum Powder Cancer Lawsuit Center website. Just as the ... talcum powder lawsuit news , offering timely lawsuit updates and ovarian cancer warning information. ...
(Date:7/3/2015)... ... July 03, 2015 , ... Yisrayl Hawkins, Pastor and ... this week that he says will reveal biblical truth and expose popular lies regarding ... Your Bible Say Don’t Have Sex”, immediately goes into the core of the subject ...
(Date:7/2/2015)... ... ... Enterprises, LLC. is pleased to announce the opening of its newest location in Dallas, Texas. ... premium frozen yogurt chain was listed as #22 on the Inc. 500 list of fastest ... Bachman Lake, is located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 , ...
(Date:7/2/2015)... ... July 02, 2015 , ... When Walker ... at the University of Minnesota, they knew it would save the university energy ... an award-winning choice: the total energy savings after installation was an impressive 89 ...
(Date:7/2/2015)... ... July 02, 2015 , ... “ LIFX ” was featured on ... technology products available to consumers. Amanda Forstrom, a technology expert and special reporter for ... most versatile smart light bulbs on the market. , According to the U.S. Department ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2
... might cause damage to DNA, study says , , ... may be at risk of DNA damage from prolonged ... that compared 83 airline pilots to 50 university faculty ... from the participants were analyzed for DNA abnormalities, specifically ...
... teens is slowing, survey finds , , THURSDAY, Dec. 11 (HealthDay ... teens, the abuse of painkillers such as Vicodin and Oxycontin ... in the use of drugs such as marijuana has stalled ... Institute on Drug Abuse says in its report, Monitoring ...
... , Dec. 11 The American Academy of Orthopaedic ... practice guideline on "Treatment of Osteoarthritis of the Knee". ... are less invasive than knee replacement surgery. While a ... be tailored to individual patients after discussions with their physicians. ...
... 11 Emerging Growth Equities, Ltd. initiates coverage of ... rating and a $9.00 price target. PolyMedix focuses ... life-threatening acute disorders. The Company,s leading clinical development ... PMX-60056. , , ...
... Appoints Carlton Turner as Chairman, Robert Schnitzius as Acting President & ... Dec 11 DelSite, Inc. (OTC Bulletin Board: DSII.OB), a drug ... board of directors for the Company, has resigned his position as ... the board until his term ends in May 2009. , ...
... of a long-term hospital stay, and ventilator-associated pneumonia (VAP), ... all people who are ventilated, is among the most ... resistance to antibiotics, patients who rely on a mechanical ... Americans do every year. , Thanks to a proven ...
Cached Medicine News:Health News:Pilots May Face Greater Cancer Risk 2Health News:10% of U.S. High School Seniors Use Vicodin 2Health News:10% of U.S. High School Seniors Use Vicodin 3Health News:AAOS Issues New Clinical Practice Guideline for Osteoarthritis of the Knee 2Health News:AAOS Issues New Clinical Practice Guideline for Osteoarthritis of the Knee 3Health News:Emerging Growth Equities, Ltd. Initiates Coverage of PolyMedix Inc. With a Buy Rating and a $9.00 Price Target 2Health News:DelSite Chairman George DeMott Resigns 2Health News:DelSite Chairman George DeMott Resigns 3Health News:There's a life-saving medical device sitting on your sink 2
Inquire...
Inquire...
Hydragel K20 is Sebia's quality line of manual agarose gel electrophoresis products. Samples are applied utilizing the same patented applicator combs that is used for sample application on the HYDRAS...
... a new device for skin extension.Thanks to ... strips, it allows a constant and powerful ... other devices capacities. Such effectiveness makes the ... it is removed before 30 days. Furthermore ...
Medicine Products: